Targeted NIR-responsive theranostic immuno-nanomedicine combined TLR7 agonist with immune checkpoint blockade for effective cancer photothermal immunotherapy
Vellingiri Yasothamani, Raju Vivek
Abstract
experiments it was demonstrated that NPs could efficiently activate PTT to induce an immune response and immune resistance based on the PD-L1 checkpoint to ablate the tumor and inhibit tumor recurrence. We confirm the potency of the NPs, which exhibit high photothermal conversion efficacy and stability. The results demonstrate that the NP combination suppresses tumor cell growth at the tumor margin beyond effective PTT and immunotherapy.
Topics & Concepts
Photothermal therapyNanomedicineTLR7BlockadeImmunotherapyCancer immunotherapyImmune checkpointCancerCancer researchMedicineAgonistMaterials scienceImmune systemNanotechnologyImmunologyNanoparticleInternal medicineReceptorInnate immune systemToll-like receptorNanoplatforms for cancer theranosticsPhotodynamic Therapy Research StudiesImmunotherapy and Immune Responses